Navigation Links
CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
Date:6/23/2008

-Study shows angina at one year associated with significantly higher

incidence of depression-

PALO ALTO, Calif., June 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that the Archives of Internal Medicine published results of a major study demonstrating that one in five patients studied experienced chest pain one year after a myocardial infarction (MI), or heart attack, and that this angina was associated with significantly elevated rates of depression among cardiac patients in the registry.

PREMIER (Prospective Registry Evaluating Myocardial Infarction: Events and Recovery) was a "real-world" observational study in nearly 2,500 patients specifically designed to characterize patients' health status one year after a heart attack. Researchers found a significant (p<0.001), consistent association between one year post-MI angina and depression across a wide range of demographic, prior history and treatment variables.

Patients with angina after one year also were more likely to smoke (p<0.001) and undergo revascularization (p<0.001). In addition, the study revealed that 21 percent of the patients with angina in the study suffered daily or weekly angina attacks.

The investigators reported that in patients with angina after one year, 87.9 percent were not taking calcium channel blockers, 30.8 percent were not taking beta blockers and 48.6 percent were not taking nitrates.

"After patients survive a heart attack, a primary goal of treatment is to minimize their angina and optimize their quality of life. The PREMIER study explicitly sought to illuminate the prevalence and predictors of angina after an MI. We found one in five heart attack survivors stil
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
2. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
3. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
4. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... Dec. 23, 2014  Advanced Medical Isotope Corporation ... primarily in the development of brachytherapy devices and ... announced that it has filed a de ... Administration ("FDA") for marketing clearance for its patented ... the U.S. Food, Drug and Cosmetic Act (the ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... BETHLEHEM, Pa., April 26, 2011 In collaboration ... for Anticancer Drug Research (CESAR) announced today that ... paclitaxel therapeutic drug management (TDM) with subsequent pharmacokinetic-guided ... non-small cell lung cancer (NSCLC).  The study will ...
... International Limited (NYSE: MR ), a leading developer, ... it will report its financial results for the first quarter ... May 9, 2011. Mindray,s management will hold an earnings conference ... Time (8:00 PM on May 10, 2011 Beijing/Hong Kong Time). ...
Cached Medicine Technology:Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 2Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 3Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 4Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer 5Mindray to Report First Quarter 2011 Financial Results on May 9, 2011 2
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... will gather for the Experimental Biology 2008 meeting in ... of the annual meeting, now in its 18th year, ... research presentations and exhibits have been selected because of ... Scientists and clinicians from dozens of different disciplines, from ...
... Jim Reynolds, MD join executive team; Jerry Noyce announces ... ... HealthFitness (OTC,Bulletin Board: HFIT) announced today that John Griffin has ... the,company as chief medical officer and Jerry Noyce has retired as ...
... BEIJING, Feb. 4 /Xinhua-PRNewswire/ -- The Red Cross ... payment service provider in China, to,launch online donation ... make online donations for snow storm victims in ... http://www.yeepay.com/mlove ., (Logo: http://www.newscom.com/cgi-bin/prnh/20051211/CNM005 ...
... follows positive phase I data from novel product candidate ... the oral ... Amira Pharmaceuticals and,GlaxoSmithKline today announced they have entered ... FLAP,(5-Lipoxygenase Activating Protein ) inhibitors for the treatment of,respiratory ...
... more than 78% , , MONDAY, Feb. 4 (HealthDay News) -- ... a new study shows it may also ease the pain ... sugar-and-water solution will also ease parents, fears and boost immunization ... to get their children vaccinated," said study author Linda Hatfield, ...
... SAP Public Services, Inc.,a subsidiary of SAP ... Corbett as vice,president of its U.S. healthcare practice. ... sector and,government-driven initiatives to improve the quality and ... be responsible for growing,SAP,s business in the U.S. ...
Cached Medicine News:Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 2Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 3Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 4Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 5Health News:Experimental Biology 2008 Today's Research: Tomorrow's Health, April 5-9 6Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 2Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 3Health News:Red Cross Partners with YeePay on China Snow Disaster Relief 2Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 2Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 3Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 4Health News:Sugar Water Eases Pain of Infant Vaccinations 2Health News:Sugar Water Eases Pain of Infant Vaccinations 3Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 2Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 3Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 4Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 5
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Woodlyn Lensmeter is designed to be used in either a prescription laboratory setting or professional office. Its titable position angle offers personal comfort. The easily operated marking device pro...
Nidek Fundus Camera NM-200D's compact, lightweight body with user-friendly color touch screen display provides more options to treat more patients, and is more comfortable to use....
Medicine Products: